112 related articles for article (PubMed ID: 10723506)
1. Hydroxyurea: mechanisms of HIV-1 inhibition.
Lori F; Lisziewicz J
Antivir Ther; 1998; 3 Suppl 4():25-33. PubMed ID: 10723506
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.
Lori F; Lisziewicz J
J Biol Regul Homeost Agents; 1999; 13(3):176-80. PubMed ID: 10560752
[TBL] [Abstract][Full Text] [Related]
5. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
[TBL] [Abstract][Full Text] [Related]
6. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
7. Deoxyribonucleotide metabolism and cyclic AMP resistance in hydroxyurea-resistant S49 T-lymphoma cells.
Albert DA; Gudas LJ; Nodzenski E
J Cell Physiol; 1987 Feb; 130(2):262-9. PubMed ID: 3029148
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
[TBL] [Abstract][Full Text] [Related]
10. Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
Davis C; Heredia A; Le N; Dominique JK; Redfield RR
J Hum Virol; 2001; 4(3):113-22. PubMed ID: 11572234
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
12. New data intensifies interest in hydroxyurea.
Santiago LG
GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
[TBL] [Abstract][Full Text] [Related]
13. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase.
Ray AS
AIDS Rev; 2005; 7(2):113-25. PubMed ID: 16092505
[TBL] [Abstract][Full Text] [Related]
14. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Zala C; Rouleau D; Montaner JS
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
Lisziewicz J; Foli A; Wainberg M; Lori F
Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
17. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
18. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
Gao WY; Zhou BS; Johns DG; Mitsuya H; Yen Y
Biochem Pharmacol; 1998 Jul; 56(1):105-12. PubMed ID: 9698094
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
Boelaert JR; Sperber K; Piette J
AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1241-7. PubMed ID: 10505672
[TBL] [Abstract][Full Text] [Related]
20. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
